Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Kidney Disease
This study is looking at a device called transcutaneous auricular vagus nerve stimulation (taVNS) for people with chronic kidney disease (CKD). The taVNS device is a type of transcutaneous electrical nerve stimulation unit (TENS) that will be applied to your right ear for 15 minutes. Researchers want to see if it's safe and tolerable, and how it affects your heart rate variability (HRV). This information will help them plan larger studies to potentially reduce heart problems in people with CKD. You might be able to join if you are 18-80 years old with CKD stage 3-5 (meaning your eGFR, a measure of kidney function, is less than 60 mL/min/1.73m2). The study is currently unclear on its recruitment status and plans to enroll 20 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It is a pilot study with 20 participants, designed to gather initial data.
- What's involved
- You would have the TENS unit applied to your ear for 15 minutes. Your heart rate variability will be measured before and after this intervention on Day 1.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your heart rate variability will be measured immediately after the intervention on Day 1. No further follow-up is specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
At a glance
Conditions
NCT05981183
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
NYU Langone Health
New York, New Yorkno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- David Charytan, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Heart Rate Variability (HRV) at BaselineDay 1 (15 minutes prior to administration of intervention)
HRV is the variation in the time interval between heartbeats.
- HRV at Post-InterventionDay 1 (15 minutes Post-Intervention)
HRV is the variation in the time interval between heartbeats.